Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
    Contact Us
  • Affiliated Brands
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    Visit JONS
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
    Visit TON
  • Healthcare Providers
  • Contribute

FDA Approvals, News & Updates

Tecvayli Received FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
Tecvayli Received FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
Multiple Myeloma, FDA Approvals, News & Updates
December 2022 Vol 8 No 6
Read More ›
Rezlidhia FDA Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Rezlidhia FDA Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
Leukemia, FDA Approvals, News & Updates
December 2022 Vol 8 No 6
Read More ›
Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
FDA Approvals, News & Updates, Lymphoma
December 2022 Vol 8 No 6
Read More ›
Elahere FDA Approved for Patients with FRα-Positive, Platinum-Resistant Ovarian Cancer
Elahere FDA Approved for Patients with FRα-Positive, Platinum-Resistant Ovarian Cancer
Ovarian Cancer, FDA Approvals, News & Updates
December 2022 Vol 8 No 6
Read More ›
Imjudo plus Imfinzi and Chemotherapy FDA Approved for Patients with Metastatic Lung Cancer
Imjudo plus Imfinzi and Chemotherapy FDA Approved for Patients with Metastatic Lung Cancer
FDA Approvals, News & Updates, Lung Cancer
December 2022 Vol 8 No 6
Read More ›
Libtayo plus Chemotherapy Now FDA Approved for Advanced Lung Cancer without Genomic Alterations
Libtayo plus Chemotherapy Now FDA Approved for Advanced Lung Cancer without Genomic Alterations
FDA Approvals, News & Updates, Lung Cancer
December 2022 Vol 8 No 6
Read More ›
Imjudo New Immunotherapy FDA Approved with Imfinzi Immunotherapy for Patients with Liver Cancer
Imjudo New Immunotherapy FDA Approved with Imfinzi Immunotherapy for Patients with Liver Cancer
FDA Approvals, News & Updates, Liver Cancer
December 2022 Vol 8 No 6
Read More ›
Enhertu First Drug Approved for Patients with HER2-Low Breast Cancer
Enhertu First Drug Approved for Patients with HER2-Low Breast Cancer
FDA Approvals, News & Updates, Breast Cancer
October 2022 Vol 8 No 5
Read More ›
Nubeqa Approved for Men with Metastatic Hormone-Sensitive Prostate Cancer
Nubeqa Approved for Men with Metastatic Hormone-Sensitive Prostate Cancer
FDA Approvals, News & Updates, Prostate Cancer
October 2022 Vol 8 No 5
Read More ›
Pemazyre Approved for Patients with FGFR1-Positive Myeloid/Lymphoid Neoplasms
Pemazyre Approved for Patients with FGFR1-Positive Myeloid/Lymphoid Neoplasms
FDA Approvals, News & Updates
October 2022 Vol 8 No 5
Read More ›

Page 1 of 16